Article in Molecular cancer therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Azam GhafoorDivision of Hematology/Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Clinical and Translational Research Center, New York, New York.ORCID 0009-0007-4349-3967
Linying ZhuUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.ORCID 0000-0002-8181-5126
Zoe Weaver OhlerCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-6287-2504
Rajaa El MeskiniCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0003-3238-7038
Haoxuan YingUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.ORCID 0000-0002-0957-9827
Devon AtkinsonCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-6675-1531
Amanda DayCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-4456-8883
Nathan PateCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0003-0409-4190
Laura BasselCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0003-1684-6839
Weixin WangDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-7693-3374
Katherine R CalvoDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-0771-4191
Lorinc PongorThoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-5917-4628
Kanak ParmarDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0003-2851-5455
Yves PommierDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-3108-0758
Anish ThomasDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0003-3293-3115
Yilun SunUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.ORCID 0000-0002-6249-2704
Funding
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore County (UMGCCC) IRG-18-160-16National Cancer Institute (NCI) 4R00CA273171-02National Cancer Institute (NCI) HHSN26120150003INational Cancer Institute (NCI) ZIA BC 011793
6 · The paper itself
Abstract
Small cell lung cancer (SCLC) is a highly aggressive malignancy, accounting for approximately 15% of all lung cancer cases. Characterized by low immunogenicity, SCLC may utilize epigenetic mechanisms to evade immune detection. In this study, we demonstrate that entinostat, a class I histone deacetylase inhibitor, upregulates immune-related genes in human SCLC cells. In vivo, we confirmed that entinostat treatment increased the expression of immune checkpoint ligands and antigen presentation machinery in Myc-driven tumors in a Rb1/Trp53/MycT58A (RPM) SCLC mouse model while shifting tumors from a neuroendocrine (NE)-high phenotype to a NE-low phenotype and was associated with increased T-cell infiltration. Notably, combining entinostat with anti-PD-1 immunotherapy suppresses tumor growth and significantly prolongs survival in RPM allograft models. These findings underscore the potential of entinostat to reprogram the NE status of SCLC, enhance immune checkpoint blockade efficacy, and improve therapeutic outcomes.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
HDAC Inhibition Unlocks Tumor Plasticity and Enhances Immunotherapy Response in Myc-Driven Small Cell Lung Cancer. · full record | OpenQuestion